Key statistics
As of last trade Innate Pharma SA (IDDA:STU) traded at 1.85, 8.82% above its 52-week low of 1.70, set on Jul 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.77 |
---|---|
High | 1.87 |
Low | 1.77 |
Bid | 1.83 |
Offer | 2.02 |
Previous close | 1.89 |
Average volume | 0.00 |
---|---|
Shares outstanding | 80.97m |
Free float | 62.13m |
P/E (TTM) | -- |
Market cap | 173.44m USD |
EPS (TTM) | -0.4628 USD |
Data delayed at least 15 minutes, as of Oct 08 2024.
More ▼
Press releases
- Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
- Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
- Innate Pharma Reports First Half 2024 Business Update and Financial Results
- Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
- Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
- Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
- Innate Pharma Announces Its Participation in Upcoming Investor Conference
- Number of Shares and Voting Rights of Innate Pharma as of July 10, 2024
More ▼